142335-67-9

Upstream product

• 51-17-2 benzoimidazole 
• 100-14-1 4-nitrobenzyl chloride 

Downstream Products

• 1313220-19-7 (4-Benzoimidazol-1-ylmethyl-phenyl)-(6-chloro-pyrimidin-4-yl)-amine 
• 1313220-20-0 (4-benzoimidazol-1-ylmethyl-phenyl)-[6-(2-methoxy-phenyl)-pyrimidin-4-yl]-amine 
• 142335-68-0 2-(4-Benzoimidazol-1-ylmethyl-phenoxy)-propionic acid ethyl ester 
• 142335-69-1 N--benzyl>-benzimidazole 
• 41833-21-0 1-(4-hydroxyphenylmethyl)-1H-benzo[d]imidazol 

Relevant academic research and scientific papers

4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY

The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group,W is a group of formula —NH—SO2—R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

4-PHENYLAMINO-PYRIMIDINE DERIVATIVES HAVING PROTEIN KINASE INHIBITOR ACTIVITY

The invention relates compounds of general formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R1 is halogen, vinylene-aryl, substituted aryl, heteroaryl or a benzo[1,3]dioxolil group, W is a group of formula -NH-SO2-R2 or heteroaryl group or NHR3 group where R3 is hydrogen or heteroaryl; and n is 1, 2, 3 or 4. Furthermore, the present invention is directed to pharmaceutical composition containing at least one compound of general formula (I) and/or pharmaceutically acceptable salts or solvates thereof and for the use of them for the preparation of pharmaceutical compositions for the prophylaxis and/or the treatment of protein kinase related, especially CDK9-related diseases e.g. cell proliferative disease, infectious disease, pain, cardiovascular disease and inflammation.

Structure-activity studies on a 1,2,3-triazole derivative, a potent in vitro inhibitor of prostaglandin synthesis: The role of the heterocyclic ring

This paper reports further structural modifications concerning the 1,2,3- triazole ring of the compound A, an effective in vitro inhibitor of prostaglandin synthesis. The introduction of different heterocyclic rings provided further information about of t